Current status of molecular targeted therapy for hematologic malignancies: introduction

被引:0
作者
Takanori Ueda
机构
[1] University of Fukui,Division of Hematology and Oncology, First Department of Internal Medicine, Faculty of Medical Sciences
来源
International Journal of Clinical Oncology | 2014年 / 19卷
关键词
Acute Myeloid Leukemia; Imatinib; Acute Lymphocytic Leukemia; Chronic Myeloid Leukemia; Hematologic Malignancy;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:1 / 2
页数:1
相关论文
共 16 条
[1]  
Coiffier B(2010)Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d’ Etudes des Lymphomes de l’ Adulte Blood 116 2040-2045
[2]  
Thieblemont C(2008)Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma J Clin Oncol 26 4579-4586
[3]  
Van Den Neste E(2007)Update on molecular-targeted therapy in hematologic malignancies Int J Clin Oncol 12 311-312
[4]  
Marcus R(2013)European LeukemiaNet recommendations for the management of chronic myeloid leukemia Blood 122 872-884
[5]  
Imrie K(2012)Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2075-2088
[6]  
Solal-Celigny P(2009)Efficacy of azacytidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study Lancet Oncol 10 223-232
[7]  
Ueda T(undefined)undefined undefined undefined undefined-undefined
[8]  
Baccarani M(undefined)undefined undefined undefined undefined-undefined
[9]  
Deininger MW(undefined)undefined undefined undefined undefined-undefined
[10]  
Rosti G(undefined)undefined undefined undefined undefined-undefined